The Anglo-Swedish drugmaker last month placed a $2 billion bet by licensing an experimental pill from China's Eccogene that it believes could cause fewer side effects than current injectable weight-loss treatments. AstraZeneca was "a few years behind" the runaway success of Novo and Lilly's drugs and was "working on the next wave of products", CEO Pascal Soriot told Reuters last month. The company is focusing on overweight population with risk factors like hypertension and kidney disease as opposed to a cosmetic market.
Low vaccination rates raise fears of COVID-19 resurgence; a survey highlights racial discrimination in health care; Eli Lilly’s tirzepatide (Zepbound) has entered US pharmacies.
Novo Nordisk, a Danish pharmaceutical company renowned for its diabetes medicines, is now positioning itself as the world s leading weight-loss company. The company aims to target the global population of 764 million people with obesity, with the United States being its most lucrative market. In the U.S., where over two-thirds of adults are either overweight or obese, Novo charges customers $1,300 per month for the weekly injection of Wegovy.
Sun Pharma, Dr. Reddy's, Lupin, Torrent, and Zydus Cadila progressing obesity drug candidates in response to rising demand. Notable developments include Sun Pharma's Phase 1 studies and Dr. Reddy’s Laboratories' permission for a semaglutide bioequivalence study
FDA Approves Eli Lilly s Obesity Drug menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.